Research Information System
International Ceramide Conference and Sphingolipid Club Joint Meeting 2015, İzmir, Turkey, 6 - 10 May 2015, pp.138, (Full Text)
Objective: Bipolar disorder (BD) is a chronic and overwhelming psychiatric condition with
manic-depressive episodes. Sphingolipids are biologically active lipids ubiquitously expressed
in the CNS. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid acting through Gprotein-coupled receptors. It has regulatory roles in endothelial injury, inflammation, and
thrombosis in vascular biology. Increase of serum S1P levels was reported to have a role in
stress-induced anxiety. In a recent study S1P receptor gene is reported as one of the
susceptibility genes in BD. We hypothesized that serum levels of S1P might have been
different among patients with manic, depressive or euthymic forms of BD.
Methods: There were three groups in the study involving euthymic (N=14), manic (N=10)
and depressive (N=7) patients. Plasma samples (100 μl) were mixed with 500 μl of methanol
containing an internal standard (IS) colchicine. Supernatants were separated after
centrifugation. An Agilent 1260 Infinity UPLC system was used for chromatography. Total
run time was 10 minutes; the flow rate was 0.5 ml/min with solvent A, water (10 mM
ammonium acetate, 0.1% formic acid) and solvent B, methanol (0.1% formic acid). The
eluent was directly introduced into a mass spectrometer by electrospray. An Agilent 6420
triple quadrupole mass spectrometer was used. S1P and IS were analyzed in positive ion mode
and multiple reaction monitoring with ion pairs 380.2/264.3 and 400.2/358.2 respectively.
Results: There was no statistically significant difference between S1P levels among groups.
Conclusion: This is a preliminary study and S1P levels should be investigated in larger
number of patients with BD.